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ABSTRACT 
Biopsies and cell lines of NK/T-cell lymphoma, nasal-type (NKTCL) were subject to 
combined gene expression profiling and array-based comparative genomic hybridization 
analyses. Compared to PTCL, NOS, NKTCL had higher transcript levels for NK-cell markers 
and cytotoxic molecules, especially granzyme H, a novel sensitive biomarker of NKTCL. 
Compared to normal NK cells, tumors were closer to activated than resting cells and 
overexpressed several genes related to vascular biology, EBV-induced genes and PDGFRA. 
Notably, PDGFRα and its phosphorylated form were confirmed at the protein level, and in 
vitro the MEC04 NKTCL-cell line was sensitive to imatinib. Deregulation of the AKT, JAK-
STAT and NF-κB pathways suggested by bioinformatical analysis, was corroborated by 
nuclear expression of phosphorylated AKT, STAT3 and RelA in NKTCL, and several 
deregulated genes in these pathways mapped to regions of recurrent copy number aberrations 
(AKT3 (1q44), IL6R (1q21.3), CCL2 (17q12), TNFRSF21 (6p12.3)). Several features of 
NKTCL uncovered by this analysis (overexpression of VEGFA and its receptor KDR by the 
tumor cells, overexpression of MET-HGF) suggest perturbation of angiogenic pathways. 
Integrative analysis also evidenced deregulation of the tumor suppressor HACE1 in the 
frequently deleted 6q21 region. This study highlights emerging oncogenic pathways in 
NKTCL and identifies novel diagnostic and therapeutic targets. 
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INTRODUCTION 
Several NK/T-cell lymphoma entities have a predilection for extranodal locations. One 
of the most common of these overall rare lymphoma entities is NK/T cell lymphoma, nasal 
type (NKTCL). The disease, most prevalent in Asian, Central and South American 
populations, most commonly arises in the nasal cavity or adjacent structures, but can also 
occur in other extranodal sites.1 This lymphoma exhibits an angiocentric and angiodestructive 
growth pattern characteristically associated with necrosis and ulceration. The tumor cells 
typically express CD2, cytoplasmic CD3 (CD3ε chain) and CD56, are negative for CD5, CD4 
and CD8 and have a cytotoxic immunophenotype with expression of perforin, granzyme B 
(gzm B), and T cell-restricted intracellular antigen (TiA1). Most cases derive from NK cells 
and lack T-cell receptor (TCR) gene rearrangement while a small proportion of cases have the 
phenotype and genotype of cytotoxic γδ or αβ T cells. Accordingly, the expression of killer 
immunoglobulin-like receptors (KIRs) has been documented in these tumors.2 
In virtually all cases, most neoplastic cells harbor clonal episomal Epstein-Barr virus 
(EBV), suggesting the implication of the virus in tumor pathogenesis. The genetic alterations 
of NKTCL reported in a few studies include gain on chromosome 2q, losses of chromosomes 
6q and 1p, and occasional presence of isochromosome 7q.3-6 
Even with intensive therapies combining multi-agent chemotherapy and involved field 
radiotherapy, the prognosis of NKTCL remains poor with 5-year overall survival ranging 
from 42% to 64% in four recent studies,7-10 and novel alternative approaches are needed. 
Several factors have been incriminated to account for aggressiveness or poor outcome, 
including Fas and p53 mutations,11,12 expression of the multidrug resistance (MDR) 1 gene 
product P-glycoprotein,13 absence of CD94 transcript14 and gzm B inhibitor PI9.9 However, 
the mechanisms involved in resistance to therapy remain poorly understood. 
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Genome-wide profiling studies of NKTCL are scarse,3,15 likely reflecting not only the 
rarity of the disease, but also quantitative and qualitative restrictions imposed by small and 
often necrotic diagnostic samples. In one recent study, Iqbal et al. focused on in-depth 
genomic and transcriptomic analysis of specific chromosomal regions, which led them to 
identify candidate suppressor genes mapping to 6q.5 In the current study, we analyzed a series 
of NKTCL samples in relation to normal cells and peripheral T-cell lymphoma, not otherwise 
specified (PTCL, NOS), with the aims to (1) characterize the molecular signature of this 
lymphoma entity, (2) explore some signaling pathways implicated in its pathogenesis, and (3) 
search for novel markers potentially useful for diagnosis and/or targetable by therapeutic 
agents. 
 
PATIENTS, MATERIALS AND METHODS 
Patient characteristics and tumor samples  
Nine newly diagnosed, previously untreated NKTCL patients with high quality RNA 
and/or DNA extracted from frozen tumor biopsies containing more than 60% tumor cells 
were selected for this study. Their main clinical, phenotypic and molecular characteristics are 
summarized in Table 1. Seven tumors originated in the nasopharyngeal area, one in the skin, 
and one in the hypophysis. All cases were reviewed by three hematopathologists (L.d.L, Y.H. 
and P.G.) and diagnosed according to the WHO criteria.1 All cases had a CD3+ (cytoplasmic), 
CD2+, CD7+, CD5-, CD4-. CD8-, TiA1+, gzm B+ phenotype. Eight cases were positive for 
EBV by in situ hybridization with EBERs probes. A high load of EBV DNA was 
demonstrated by PCR in the remaining case. Specimens were also investigated for TCR 
γ chain gene rearrangement using a GC-clamp multiplex polymerase chain reaction (PCR)-γ-
DGGE procedure. Seven cases without clonal T-cell population were regarded as of NK-cell 
origin, and a cytotoxic T-cell derivation was established in two cases with a clonal TCR gene 
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rearrangement. For immunohistochemical validation, formalin-fixed, paraffin-embedded 
tumor samples from 16 NKTCL, including seven of the cases described above, and 17 PTCL, 
NOS were selected. 
The present study was approved by the institutional review board “Comité de 
Protection des Personnes Ile de France IX”, Créteil, France. 
 
Cell lines and normal NK cells  
Two NKTCL cell lines, SNK6 and SNT8 (Table 1),16 and two samples of normal CD56+ NK 
cells purified from peripheral blood including resting and IL-2-activated NK cells, were also 
subjected to gene expression profiling. The MEC04 NKTCL cell line was also used for in 
vitro proliferation assay and immunohistochemical validation.17 U937, a myelomonocytic cell 
line (ATCC LGC Standards, Molsheim, France), was used as control for in vitro assay. Cell 
lines were cultured in RPMI 1640 supplemented with 2 mM L-glutamine and 10% heat-
inactivated fetal bovine serum (Invitrogen, Carlsbad, CA) in the presence of 100 U/ml 
recombinant human IL-2, except for U937 cell line. Centrifugated pellets of SNK6 and 
MEC04 cells were fixed in ethanol to construct paraffin-embedded blocks. 
 
RNA and DNA extraction 
Total RNA was extracted with TRIZOL reagent (Invitrogen, Carlsbad, CA), according to the 
manufacturer's instructions, and DNA was extracted with phenol-chloroform using standard 
procedures. The integrity of the extracts was verified on an Agilent 2100 Bioanalyser (Agilent 
Technologies, Palo Alto, CA, USA). 
 
Microarray procedures 
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Microarray analyses were performed using 3 μg total RNA as starting material and 10 μg 
cRNA per hybridization (GeneChip Fluidics Station 400; Affymetrix, Santa Clara, CA). The 
total RNAs were amplified and labeled following the one-cycle target labeling protocol 
(http://www.affymetrix.com). The labeled cRNAs were hybridized to HG-U133 plus 2.0 
Affymetrix GeneChip arrays (Affymetrix, Santa Clara, CA). The chips were scanned with an 
Affymetrix GeneChip Scanner 3000 and subsequent images analyzed using GCOS 1.4 
(Affymetrix). 
 
Gene expression analyses 
The gene expression analysis encompassed HG-U133 plus 2.0 Affymetrix array data from 
seven NKTCL biopsies, two NKTCL cell lines (Table 1), 16 PTCL, NOS recently reported by 
our group under accession number E-TABM-702,18 six normal NK cells samples (including 
four previously published from GSE8059),19 eighteen recently published normal B cell 
samples (eight from GSE15271 and 10 from GSE12195),20,21 and 15 activated B-cell-like 
diffuse large B-cell lymphoma (ABC-DLBCL) samples from GSE12195.21 Two NK cell 
samples without stimulation of IL-2 (one each from ours and from GSE8059) represented the 
“resting NK cell” group, while the two NK cell samples stimulated by IL-2 for 24 hours (one 
from our sample, the other from GSE8059) were regarded as the “activated NK cell” group. 
Affymetrix raw data of the samples were normalized in batch using Robust Multichip 
Average (RMA) method along with 58 other samples unrelated to this study. The clustering 
analysis of the 25 tumor samples was performed as already described.22 To identify genes 
differentially expressed between two groups of samples we used Welch’s T-tests. To control 
for multiple testing, we measured the local false discovery rate using kerfdr R package, an 
alternative approach to the more commonly used Bonferroni and Benjamini-Hochberg 
methods.23 The KEGG / Biocarta pathways enrichment scores were calculated by combining 
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four methods including Significance Analysis of Microarray to Gene-Set Analysis (SAM-
GS), Gene Set Analysis (GSA), and globaltest. The median score across the four methods was 
used to rank the pathways. Methodological details are given in the Supplementary Materials 
and Methods (Method S1). Raw gene expression data have been deposited to ArrayExpress 
under accession number E-TABM-702. 
 
Array-based comparative genomic hybridization (aCGH) 
Genome analyses of eight NKTCLs, SNK6 and SNT8 cell lines were performed using the 
human genome-wide CIT-CGH array (V6) containing 4434 sequence verified bacterial 
artificial chromosome (BAC) clones (with quadruplicate spots per clone) with a median gap 
between two successive clones of 600 kb. The characteristics of this array have been 
previously reported. aCGH raw data (deposited to ArrayExpress under accession number E-
TABM-791) were normalized using the within print-tip group lowess method; smoothing, 
breakpoints detection and status (Gain/Loss) determination were calculated using the 
Bioconductor package GLAD. Methodological details are given in the Supplementary 
Materials and Methods (Method S1). 
 
Immunohistochemistry 
Immunohistochemistry was performed on deparaffinized tissue sections using a standard 
indirect avidin-biotin immunoperoxidase method. After appropriate antigen retrieval, sections 
were stained for EBI3 (2G4H6);24 pSTAT3 at Tyr705 (D3A7), pAKT at Ser473 (736E11) 
(Cell Signaling Technology, Danvers, MA); VEGFA (C1), VCAM-1 (E10), cRel (B-6), 
PDGFRα and pPDGFRα (Santa Cruz Biotechnology, Santa Cruz, CA); E-cadherin (NCH-38, 
DakoCytomation, Glostrup, Denmark); CD163 (10D6, Novocastra-Leica, Wetzlar, Germany); 
clusterin (41D, Upstate-Millipore, Billerica, MA); CCND1 (SP4, Lab Vision-Thermo Fisher 
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Scientific, Fremont, CA); epidermal growth factor receptor (EGFR) (31G7, Zymed-
Invitrogen, Carlsbad, CA); β-catenin (14, BD Biosciences, Erembodegem, Belgium); RelB 
(EP613Y, Epitomics,  Burlingame, CA). For granzyme H (gzm H) (4G5)25 and RelA (Santa 
Cruz Biotechnology), tyramide signal amplification system (CSAII kit, DakoCytomation) and 
peroxidase-labeled destran polymer (EnVision+, DakoCytomation) were applied, 
respectively. Adequate control tissues for specific antibodies were included. 
 
Quantitative reverse-transcriptase PCR analysis of candidate genes 
The expression of candidate genes (HACE1, CCL2, TNFRSF21, CCND3, MET) identified in 
altered chromosomal regions was determined by TaqMan® quantitative reverse-transcriptase 
PCR (qRT-PCR) (Applied Biosystems, Foster City, CA) in six primary tumors, three NKTCL 
cell lines and in resting normal NK cells as control. The expression of HACE1 was compared 
to that of PRDM1, ATG5 and AIM1, three candidate tumor suppressor genes in NKTCL also 
mapping at 6q21.5 All primers and probes were purchased from Applied Biosystems and the 
gene expression was measured using Mastercycler® ep realplex2S system (Eppendorf, 
Hamburg, Germany). Quantifications were done in duplicate and mean values and standard 
deviation were calculated for each transcript as previously described.26 
 
PDGFRA gene analysis 
PDGFRA gene analysis was performed in six primary tumors and in three cell lines. 
PDGFRA copy numbers in intron 1 (Syst: Hs05935655_cn,hg18.v7) and exons 7-8 (Syst: 
Hs04818823_cn,hg18.v7) were measured on a LightCycler 480 (Roche Diagnostics, Meylan, 
France), using TaqMan® copy number assays according to the manufacturer’s instructions 
(Applied Biosystems). ALB gene was used as the reference gene.27 
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 The mutations of PDGFRA exons 12, 14 and 18 were searched by Length Analysis 
of PCR Products (LAPP) and sequencing as described previously.28 
 To search for mutations and polymorphisms in the PDGFRA promoter region, 
genomic DNA was amplified by PCR using the primers 1651F and 727R as described by 
Toepoel et al.29. After purification (PCR purification kit, GE Healthcare, Freiburg, Germany), 
automated sequencing was performed on the ABI310 genetic analyzer with the Big Dye 
terminator sequencing kit (Applied Biosystems) using the primers 1562F, 1340R, 1110F, and 
759R (see supplementary data). Sequences were compared to the reference sequence for 
PDGFRA promoter (GenBank accession number X80389). 
 
3H thymidine-labeled proliferation assay 
Cells were washed extensively to remove IL-2 and plated at 20,000 cells per well, in the 
presence or absence of imatinib mesylate (Axon Medchem BV, Groningen, The Netherlands), 
at 3 different concentrations (1, 3, and 6 µM) and incubated for 72 hours. One µCi of tritium 
thymidine was added 6 hours before evaluating the proliferation using Packard TopCount 
Liquid Scintillation Counter (GMI, Ramsey, MN). Results were expressed as the percentage 
of proliferation measured in the absence of inhibitor. All experiments were performed in 
triplicate. 
 
RESULTS  
The molecular signature of NKTCL differs from that of normal NK cells 
The Affymetrix expression profiles of seven NKTCL samples were compared with those of 
normal NK cells (n=6). A total of 2447 and 2339 probe sets corresponding to 1721 and 1436 
overexpressed and underexpressed genes, respectively, significantly distinguished NKTCL 
tissues from normal NK cells (P < 0.005) (Tables 2 and S1). As expected, genes related to the 
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microenvironment, notably macrophages (CLU, CD68, CD163) were among the most 
differentially overexpressed in NKTCL tissues. As shown in Tables 2 and S1, the other genes 
overexpressed in NKTCL tissues included genes involved in the autophagy (ATG3, ATG7) 
and in the cell cycle control (CCND1), related to cell-to-cell interactions (CDH1, ITGA7, 
ITGA9, ITGB4, VCAM1), chemokines (CX3CL1, CXCL9, CXCL10), cytokines (IL8, IL20, 
IL33), extracellular matrix (ECM) interactions (MMP11, MMP14, TIMP1, TIMP2, TIMP3), 
innate immunity (IL4I1, TLR4, TLR7, TLR8), local invasion and metastasis (COL1A1, 
COL1A2, FN1, LAMB1), angiogenesis (ANGPT2, VEGFA, VEGFB, VEGFC, KDR), growth 
factors and their receptors (PDGFRA, PDGFB, PDGFC, TGFB2, TGFB3), oncogenes 
(MAFB, MET, MYC) and genes reported to be induced by EBV in vitro (CDH1, EBI3, 
BASP1, DNASE1L3, HCK, HLA-DQA1, IFI30, IFI44L, IFITM3, LGALS9, THRA, 
TNFRSF10D).15,30 PCDH15, a gene previously shown to be specifically expressed in 
NKTCLs31 was also overexpressed, albeit with less statistical significance. Some of these 
genes were also overexpressed in SNK6 and SNT8 cell lines compared to normal NK cells, 
for example, VCAM1, CXCL10, EBI3, TIMP1, MYC, PDGFRA, KDR and VEGFA (Tables 2 
and S1). Interestingly, NKTCL appeared to be more closely related to activated than to resting 
NK cells, as the level of expression of about two-thirds of the NKTCL signature was closer to 
that of activated NK cells than that of resting NK cells. 
Among these overexpressed genes tested by immunohistochemistry, E-cadherin, 
CD163, clusterin, EGFR, and cyclin D1 expression was restricted to non-neoplastic cells, i.e. 
epithelial cells (E-cadherin, clusterin, cyclin D1, EGFR), stromal cells (clusterin, cyclin D1) 
and numerous histiocytes (CD163) (Table 3). By contrast, VCAM1 and the EBV-induced 
gene 3 (EBI3), a subunit of IL-27, labeled the neoplastic cells of 4/13 (31%) and 9/12 (75%) 
evaluable NKTCLs, respectively (Figure 1B). SNK6 and MEC04 cells were also positive for 
EBI3. 
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NKTCL has a distinct molecular signature compared to PTCL, NOS 
Unsupervised, consensus clustering applied to the molecular signatures of nine NKTCL 
samples (seven biopsies and two cell lines) and 16 PTCL, NOS samples, generated two main 
branches correlated to the pathological diagnosis. Indeed, all NKTCL samples clustered in 
one branch, and the other branch comprised PTCL, NOS cases only (Figure 2). Interestingly, 
one case of nodal γδ PTCL, NOS with an activated cytotoxic profile (gzm B+) but negative 
for EBV (sample C2) clustered with NKTCL cases. 
By supervised analysis, a total of 372 and 691 probe sets corresponding to 278 and 
484 overexpressed and underexpressed genes, respectively, significantly distinguished tissues 
involved by NKTCLs versus PTCLs, NOS (P < 0.005) (Tables 4 and S2). As expected, 
among the top overexpressed genes in NKTCLs were many genes encoding KIRs, and others 
encoding NK-cell associated molecules (NCAM1, CD244) or related to cytotoxic functions 
(GZMB, GZMH, CTSW, PRF1…). Significantly, NKTCLs also overexpressed genes encoding 
cell adhesion molecules (ITGAM, ITGB6), chemokines and their receptors (CCL4, CCL5, 
CCR1), apoptosis-related molecules (FASLG, BCL2L2), cytidine deaminase (APOBEC3G), 
and oncogenes (MYC, RHOC). In addition to NCAM1 (CD56) and cytotoxic proteins such as 
TiA1 and gzm B which were strongly expressed in all NKTCLs, we investigated the 
expression of another cytotoxic granule-associated protein, gzm H, of which transcript levels 
were 13.66 times higher than in PTCLs, NOS. As shown in figure 1, a strong granular 
cytoplasmic staining was found in virtually all neoplastic cells of all NKTCL tumors tested 
(n=16) as well as in the SNK6 and MEC04 cells whereas gzm H was restricted to small 
lymphocytes in most PTCLs, NOS. Among PTCL, NOS, the γδ T-cell lymphoma was gzm H 
positive and another case disclosed heterogeneous partial staining. 
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Patterns of copy number aberrations and identification of genes relevant to the 
pathobiology of NKTCL 
The aCGH findings are summarized in Table 5 and in Figure 3. Extensive losses and gains of 
larger and smaller chromosomal regions were found in all NKTCL samples analyzed. 
Recurrent copy number aberrations (CNA) observed in ≥ 3/8 (37.5%) NKTCL biopsy 
samples, comprised 16 regions of chromosomal gains (on 10p15, 7q35-q36, 7p11.2-p12, 
7q11.2-q34, 16p13.3, 17q12 and on 1q21-q44, 4p16, 6p11.1-p25, 6q11.1-q14, 6q27, 8p23.3, 
9q34, 10p14-p15, 11p15, and 22q11.21) and four regions of losses (on 6q16-q25, 11q24-q25, 
17p13.3, and 8p22-p23). 
 To identify candidate genes in the regions of CNA, we selected the genes with a 
Welch’s T-test P-value less than 0.001 and a fold average expression difference > 2.0 (or < 
0.5) in NKTCL tissues compared to normal NK cells. The resulting list (Table S3) included 
genes related to malignant transformation and invasion (S100A16, LAMB1, LAMC1, COL1A2, 
CTSB), cell cycle progression (CCND3), signal transduction (FYN), tumor suppressor genes 
(HACE1, CAV1, CAV2, DLC1), as well as members of important pathways which, according 
to GEP analysis, appear deregulated in NKTCL (see below), such as angiogenesis (MET, 
S100A13), NF-κB (PRKCQ, TNFRSF21), WNT (CUL1, FZD1, SGK1), and JAK-STAT 
(AKT3, IL6R, CCL2) signaling pathways.  
 We selected for qRT-PCR correlation several biologically relevant deregulated 
candidate genes mapping to altered chromosomal regions at 6q21 (HACE1), 17q12 (CCL2), 
6p12.3 (TNFRSF21), 6p21.1 (CCND3), 7q31.2 (MET). We also evaluated ATG5, AIM1, 
PRDM1 genes reported as candidate tumor suppressor genes at 6q21 in NKTCL cell lines, 
that were downexpressed in our microarray data albeit at less statistical significance. In 
agreement with the microarray results, we confirmed by qRT-PCR the overexpression of 
MET, CCL2, TNFRSF21 in NKTCL samples compared to normal NK cells and the 
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underexpression of CCND3 and HACE1 (Figure 4). ATG5 and AIM1 transcripts were also 
markedly reduced in both cell lines and primary tumors. In contrast, quantification of PRDM1 
mRNA gave discrepant results in cell lines (underexpressed levels, in accordance with 
published data5) and primary tumors.(increased transcript levels in four of six samples). These 
findings were independent of the presence or absence of 6q21 deletion. 
 
Identification of distinct pathways in NKTCL 
In order to identify potentially relevant biological pathways in NKTCL, four gene sets 
analysis methods were applied. The most discriminatory pathways when comparing NKTCL 
and normal NK cells or PTCL, NOS, comprised those related to important cell functions such 
as apoptosis, cell adhesion, cell communication, ECM-receptor interaction, cell cycle (p27 
regulation), cytokine-cytokine receptor interaction, as well as TGFβ, MAPK, WNT and JAK-
STAT signalling pathways (Table 6, Figure 5A and E). More specifically, angiogenesis-
related (VEGF) and NF-κB were also discriminatory pathways between neoplastic samples 
and normal NK cells. FAS and AKT signaling genes pathways and especially genes related to 
NK-cell mediated cytotoxicity (Figure 5B, C, D, and F) were differentially expressed between 
NKTCL and PTCL, NOS. 
For example, as illustrated in Figure 5A, several component genes of JAK-STAT 
pathway like IL13RA1, IL6R, STAT1, STAT2, VEGFA, CCND1 and MYC were overexpressed 
in NKTCL compared to normal NK cells and IL12RB1, IL20, IL2RB, and MYC compared to 
PTCL, NOS. Altogether, the pathway analysis supports the involvement of several important 
pathways in NKTCL. 
 
Activation of several oncogenic pathways (AKT, STAT3, NF-κB, VEGF) in NKTCL 
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In order to evaluate the possible activation of pathways identified using statistical methods, 
the expression of several representative genes was assessed at the protein level (Table 3 and 
Figure 1). Nuclear expression of phosphorylated AKT (Ser473) and STAT3 (Tyr705) was 
found in 9/9 and 13/14 NKTCL cases, respectively. Strong expression of VEGFA, one of the 
important STAT3-regulated gene products related to angiogenesis and immune evasion,32 was 
demonstrated in 9/9 NKTCL and expression of its receptor VEGFR2 was evidenced in the 
neoplastic cells of 4/5 tumors. Positivity for pSTAT3 and VEGFA was confirmed in MEC04 
and SNK6 cell lines, and pAKT was demonstrated in MEC04 cells. 
Differential expression of WNT and NF-κB pathway genes were also identified in 
pathway analyses. Nuclear expression of β-catenin, a hallmark of activation of WNT 
pathway, was not observed in neoplastic cells (n=8), contrasting with cytoplasmic and/or 
membrane staining in surrounding epithelial and endothelial cells. On the other hand, RelA 
and cRel, two important molecules of the canonical NF-κB pathway, were expressed in the 
cytoplasm of most evaluable NKTCLs associated with nuclear localization of RelA (Figure 
1). RelB, a molecule of the alternative NF-κB pathway, was negative in all investigated 
NKTCLs (n=6). 
 
Activation of PDGFRA pathway in NKTCL 
Since PDGFRα a receptor tyrosine kinase mediating important cell functions such as 
migration, proliferation and cell survival and known to interact with PI3K/AKT and STAT 
proteins,33 was highly expressed at the mRNA level (Table 2 and Figure 5B), this factor was 
evaluated by immunohistochemistry. Eleven of 13 (85%) NKTCL cases showed cytoplasmic 
expression of PDGFRα. In addition, its phosphorylated form (pPDGFRα) was found in all 13 
NKTCLs (Table 3 and Figure 1). In agreement with a recent report,34 expression of both 
PDGFRα and pPDGFRα was also demonstrated in most PTCLs, NOS (Table 3). In view of 
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these findings, we investigated the potential implication of the PDGF signaling pathway in the 
proliferation of NKTCL cells. Imatinib mesylate induced dramatic concentration-dependent 
growth inhibition of PDGFRα-positive MEC04 cells whereas the effect on SNK6 cells was 
minimal. As shown in Figure 6, a significant 50% growth inhibition was already observed 
when MECO4 cells were exposed to imatinib mesylate at 1µM that increased to 90% at 6 µM. 
U937 used as a control cell line known to be resistant to imatinib mesylate maintained 63 % 
proliferation with 6 µM imatinib. 
 We further searched for potential genetic alterations underlying PDGFRA 
deregulation. The absence of copy number gain in PDGFRA locus validated by real-time PCR 
in eight interpretable samples was concordant with the absence of genomic imbalance in 
4q11-q13 observed in our BAC array CGH data. In addition, we did not evidence mutations 
in exons 12, 14 and 18 of PDGFRA, in agreement with previous findings.35 
 Finally, we performed mutations and polymorphisms analysis within the PDGFRA 
promoter region and in particular investigated the distribution of haplotypes which have been 
reported in association with different transcriptional activities.36 Sequence analysis did not 
show any mutation in the nine samples tested (compared to the reference sequence), and the 
distribution in the haplotypes - four samples had a H1/H2α genotype, three H2α/H2α, one 
H2α/H2β and one H2α/H2γ  − corresponded to that reported in the Western European 
population (see supplementary data). 
 
DISCUSSION 
In the present study, we characterized the molecular signature of NKTCL in comparison to 
normal NK cells and to PTCL, NOS. This led to the identification of deregulated genes and 
signaling pathways which might be relevant to the pathophysiology and clinicopathologic 
features of the disease and bring rationale for the development of new therapies. 
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Unsupervised clustering remarkably segregated NKTCL and PTCL, NOS samples. 
Notably, the NKTCL case with a T-cell cytotoxic phenotype (sample T5) clustered with those 
of NK cell origin, providing another molecular argument for grouping nasal “true NK-” and 
cytotoxic T-cell lymphomas as a single entity as proposed in the current WHO classification.1 
Interestingly, the NKTCL case of T-cell derivation also showed the 6q16-q25 deletion. The 
only mismatch was represented by one PTCL, NOS in the NKTCL cluster. That particular 
case had a γδ activated cytotoxic phenotype suggesting that derivation from the innate 
immune system might imprint a peculiar signature.37 
By comparison to PTCL, NOS, the molecular signature of NKTCL was significantly 
contributed by an overexpression of genes associated with cytotoxic functions and NK-cell-
associated molecules. Interestingly, the highest fold change of expression was observed for 
gzm H transcripts. Granzyme H, a gzm family member sharing a 90% amino acid sequence 
identity with gzm B, is constitutively expressed in NK cells irrespective of their activation 
status25 but acts differently from gzm B by inducing a caspase-independent cell death 
program.38 We confirmed a strong gzm H protein expression in all NKTCLs contrasting with 
its negativity in most PTCLs, NOS, with the notable exception of the γδ T-cell lymphoma. 
Therefore, gzm H appears to be a novel sensitive marker for NKTCL, although its specificity 
needs to be delineated with respect to its possible expression in other lymphomas derived 
from the innate immune system. 
Other aspects of the NKTCL signature could be related to some peculiar 
clinicopathologic features of the disease. Angioinvasion and angiocentricity typical of 
NKTCL, might be accounted by the high expression of genes such as VCAM1, CXCL9, and 
CXCL10, encoding proteins involved in the interaction with endothelium or in the 
pathogenesis of tissue necrosis and vascular damage associated with EBV-positive 
lymphoproliferations.39 NKTCL, which in most instances arises in the nasal area, is also 
17 
characterized by a strong tendency to disseminate to other extranodal distant sites. In view of 
the known roles of CCR7 and SELL/CD62L in peripheral lymph node homing and that of 
CCL27, CXCL12, in homing to the skin, intestine and bone marrow, it is likely that the lower 
levels of CCR7 and SELL/CD62L and the overexpression of CXCL12 might explain the 
pattern of distribution of the disease. 
We confirmed here recurrent genomic gains and losses previously reported in 
NKTCL. Deletion of chromosome 6q reported as the most characteristic but not specific 
genetic alteration in NKTCL,3-5,40-42 was present in 40% of our cases, including SNK6 cell 
line. In line with the recent report by Iqbal et al., we also found recurrent gain of 1q21-q44 
and loss of 17p13.3 in primary tumor samples.5 These authors found PRDM1, ATG5, and 
AIM1 as target genes in the region of del6q21 and reported both mutation and methylation in 
PRDM1. Here, we further extended these previous findings by showing low levels of ATG5 
and AIM1 transcripts in primary tumors. Conversely, PRDM1 showed a wide range of 
expression from case to case. In addition, we also found marked reduction in transcripts of 
HACE1, a gene encoding a novel E3 ubiquitin ligase, which is the target of epigenetic 
inactivation in Wilms’ tumor and has been proposed as a tumor suppressor gene in multiple 
human cancers. Hace1-/- mice are spontaneously prone to developing multiple malignant 
tumors in various organs.43 Taken together, it is therefore tempting to speculate that HACE1 
might be also involved in the pathogenesis of NKTCL. 
The proto-oncogene MET mapping in 7q31, a region of recurrent gain in our series, 
was overexpressed in our samples. This receptor with tyrosine-kinase activity is a receptor to 
HGF, also overexpressed at the mRNA level in our NKTCL series. Interestingly, this pair of 
ligand-receptor appears to be linked to angiogenesis, tumor formation, invasion, and 
metastasis.44 These findings, together with the expression of VEGFA and its receptor 
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VEGFR2 might reflect the implication of angiogenesis and/or VEGF signaling pathway in the 
pathophysiology of NKTCL. 
The molecular pathways involved in the pathogenesis of NKTCL are largely 
unknown. Our study identified deregulated pathways in NKTCL, in comparison to normal 
NK cells and PTCL, NOS. Among growth factor receptors, the receptor tyrosine kinase 
PDGFRα was expressed at a higher level than in normal NK cells, both at the mRNA and 
protein levels, in its activated phosphorylated form, a feature which appears to be shared with 
PTCL, NOS.34 PDGF signaling pathway is known to be associated with both JAK-STAT and 
AKT pathways. The AKT protein kinases play a critical role in cell proliferation, survival and 
programmed cell death, transcription, and cell migration via phosphorylation of a multitude of 
substrates. Signal transducers and activators of transcription (STATs) are transcription factors 
activated in response to cytokines and growth factors. STAT3 in particular plays a crucial role 
in regulating cell growth and apoptosis.32 Several solid or hematological malignancies 
including ALK-positive anaplastic large cell lymphomas show constitutive STAT3 activation. 
Using statistical methods, we showed here that AKT and JAK-STAT pathways were 
differentially expressed in comparison to normal NK cells and/or PTCL, NOS. In addition, we 
evidenced the nuclear expression of the phosphorylated forms of STAT3 and AKT in most 
NKTCLs implying constitutive activation of these pathways in this disease. Our results 
expand recent findings that AKT was phosphorylated in NK-92 cell line and in a few NKTCL 
primary tumors, probably through involvement of IL-2 or IL-15.45 Many genes related to 
proliferation and survival, angiogenesis, and immunosuppression are known to be regulated 
by STAT3.32 The high transcript levels of several genes regulated by STAT3 in NKTCL 
compared to normal NK cells such as MYC, VEGFA, BCL2L1, - and also less significantly 
BIRC5, HGF, IL6, MMP2, MMP9, IL10, and CDK5 - suggests its implication in the 
pathogenesis of NKTCL. Among these, MMP2, MMP9 and IL-10 proteins have already been 
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evidenced in NKTCL tumor cells and we show here immunohistochemical expression of 
VEGFA.46,47 Recently, we demonstrated that the inhibition of STAT3 activation leads to 
underexpression of two STAT3 target gene products, BCL-XL and MYC in MEC04 cells.17 
Altogether, these data provide strong arguments supporting the involvement of JAK-STAT 
and AKT pathways in NKTCL (Figure 7). 
EBV, constantly present in NKTCL, is suspected to play an important role in 
oncogenesis. Here we showed that, in comparison to EBV-negative normal NK cells, NKTCL 
overexpressed several EBV-induced genes.15,30 In agreement with a previous report,24 one of 
these genes, EBI3, was validated at the protein level. Among the various mechanisms 
involved in NF-κB pathway, EBV is known to activate NF-κB pathway through LMP-1 
and/or TRAF,48 especially in Hodgkin lymphoma and in EBV-positive B-cell 
lymphoproliferative disorders. Here, we showed differential expression of this pathway in 
NKTCL and further demonstrate expression of RelA, supporting activation of NF-κB in this 
entity. Interestingly, TNFAIP3 gene, encoding an inhibitor of the NF-κB pathway, maps to the 
region of recurrent loss in 6q16-q25 and was underexpressed in our study. Deletions and/or 
somatic mutations of this gene have been recently reported in classical Hodgkin lymphoma 
and primary mediastinal B-cell lymphoma as well as in MALT lymphoma49,50 supporting the 
role of this key regulator of NF-κB activity as a novel tumor suppressor gene in these 
lymphomas. Altogether, these findings suggest the involvement of NF-κB pathway in the 
pathogenesis of NKTCL. The respective role of EBV and/or TNFAIP3 inactivation in NF-κB 
activation in NKTCL needs further investigation. 
The demonstration of pPDGFRα by immunohistochemistry prompted us to test the 
sensitivity of NKTCL cell lines in vitro to imatinib mesylate. The effect of the drug already 
significant at a 1µM concentration with a 50% growth inhibition on MEC04 cells, was most 
prominent (90% inhibition of growth) at 6µM. Conversely, there was no substantial cytotoxic 
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effect on the SNK6 cell line, which might be related to a lower expression of PDGFRA, as 
suggested at the RNA level (Figure 3). Although our results do not preclude the precise 
mechanism of action of imatinib and suggest heterogeneity in the sensitivity to the drug, the 
dramatic effect on MEC04 cells shed light on the possible use of tyrosine kinase inhibitors as 
a novel therapeutic option in some patients with NKTCL refractory to conventional therapies. 
 The cause of PDGFRA deregulation in NKTCL remains to be determined. We did 
not evidence either genomic imbalances or gene mutations. Furtheremore, mutations in the 
promoter region were absent in NKTCL primary tumors and cell lines, and we did not find 
overrepresentation of H2α haplotype, known to result in upregulation of PDGFRA in 
glioblastoma.29 
In conclusion, this integrative genomic and transcriptomic study characterizes the 
molecular signature of NKTCL, highlights emerging oncogenic pathways in this disease 
entity and offers rationale for exploring new therapeutic options such as tyrosine kinase 
inhibitors in patients with this aggressive malignancy. 
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Table 1. Summary of immunohistochemical, and genotypic features of the NKTCL samples analysed in the study. 
Samples Age Sex Biopsy site CD3ε CD2 CD5 CD7 CD4 CD8 CD56 TiA1 Gzm B EBV T clonality 
T1 58 M Nasopharyngeal region + + - + - - + + + + - 
T2 25 M Nasopharyngeal region + + - - - - + + + + - 
T3 64 M Skin + - - ND - - - + + + - 
T4 62 M Nasopharyngeal region - + - - - - + + + + - 
T5 72 M Nasopharyngeal region + + - - - - + + + + + 
T6 52 F Nasopharyngeal region + + - - ND - + + + + - 
T7* 42 M Hypophysis + + - - + - + + + + - 
T8† 31 F Nasopharyngeal region + + - + + ND + + + + - 
T9† 67 M Nasopharyngeal region + + - + - + + + + + +‡ 
SNK6 NA NA NA + + ND ND - - + ND + + - 
SNT8 NA NA NA + + ND ND - - + ND ND + + 
*: sample used only for transcriptomic analysis. 
†: samples used only for genomic analysis. 
‡: this case showed βF1 immunoreactivity on formalin-fixed paraffin-embedded tissues sections, and was negative for δTCR1 on frozen sections. 
NA: not applicable. 
ND: not done. 
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Table 2. Selection of genes overexpressed in NKTCL tissues compared to normal NK 
cells with P-value less than 0.005. A complete list of genes is given in the supplementary 
table S1. 
Gene class and specific genes Fold change 
Cell-to-cell interactions 
CDH1 (E-cadherin)* 1.54 
ITGA9 (Integrin alpha 9) 2.37 
ITGB4 (Integrin beta 4)* 2.15 
VCAM1 (Vascular cell adhesion molecule 1)* 26.18 
Cell cycle control 
CCND1 (Cyclin D1)* 6.67 
Chemokines 
CCL18 10.50 
CCL19 80.67 
CCL2* 88.11 
CCL8* 51.61 
CXCL10 (IP10)* 48.07 
CXCL12 (SDF-1) 25.75 
CXCL9 (Mig) 254.14 
Cytokines 
IL13RA1* 9.19 
IL6R 2.25 
IL33* 2.75 
IL8* 5.07 
Genes overexpressed in EBV-infected lymphoma cell lines 
EBI3 (EBV induced gene 3)* 2.76 
BASP1 (Brain abundant, membrane attached signal protein 1)* 13.21 
HCK (Hemopoietic cell kinase) 16.01 
TNFRSF10D (Tumor necrosis factor receptor superfamily, member 10d)* 1.53 
Extracellular matrix interactions 
COL1A1 (Collagen, type I alpha 1)* 45.91 
COL1A2 (Collagen, type I alpha 2)* 33.35 
COL3A1 (Collagen, type III alpha 1)* 59.68 
FN1 (Fibronectin 1)* 91.79 
TIMP1 (TIMP metallopeptidase inhibitor 1)* 6.28 
TIMP2 (TIMP metallopeptidase inhibitor 2) 10.79 
TIMP3 (TIMP metallopeptidase inhibitor 3) 9.57 
Growth factors & receptors 
GHR (Growth hormone receptor)* 1.35 
PDGFB (Platelet-derived growth factor beta)* 2.16 
PDGFC (Platelet derived growth factor C)* 7.92 
PDGFRA (Platelet-derived growth factor receptor, alpha polypeptide)* 7.47 
Immunity & lymphocyte development 
CD86* 6.04 
HLA-DOA* 12.12 
HLA-DRA* 12.18 
IL4I1 (Interleukin 4 induced 1)* 6.40 
SLAMF8 (SLAM family member 8)* 45.26 
TLR2 8.76 
TLR7* 5.26 
TLR8 13.49 
Microenvironment 
CD163 134.47 
Oncogenes 
MAFB (V-maf musculoaponeurotic fibrosarcoma oncogene homolog) 37.94 
MET (Hepatocyte growth factor receptor))* 2.00 
MYC* 1.23 
Transcription factors 
STAT1* 5.25 
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STAT2* 1.86 
Vascular biology 
KDR (VEGFR2)* 1.47 
THBD (Thrombomodulin) 4.33 
VEGFA* 1.54 
VEGFC* 1.68 
VWF* 12.97 
Miscellaneous 
AIM2 (Absent in melanoma 2)* 14.76 
CD40 (TNF receptor superfamily member 5)* 3.95 
FZD1 (Frizzled homolog 1)* 2.55 
*: genes are also overexpressed in NKTCL cell lines compared to normal NK cells.
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Table 3. Summary of immunohistochemical results*. 
 
NKTCL 
(n=16) 
NKTCL cell 
lines (n=2) 
PTCL, NOS 
(n=17) 
Clusterin 0/4 (0%) 0/1 ND 
E-cadherin 0/4 (0%) ND ND 
Cyclin D1 0/4 (0%) ND ND 
EGFR 0/4 (0%) ND ND 
CD163 0/4 (0%) 0/2 ND 
EBI3 9/12 (75%) 2/2 1/13 (8%) 
VCAM1 4/13 (31%) 0/2 0/7 (0%) 
Granzyme H 16/16 (100%) 2/2 2/16 (13%) 
pSTAT3 13/14 (93%) 2/2† 2/17 (12%) 
pAKT 9/9 (100%) NE 0/16 (0%) 
VEGFA 9/9 (100%) 2/2 5/13 (38%) 
VEGFR2 4/5 (80%) 2/2‡ ND 
PDGFRα 11/13 (85%) 1/1 10/10 (100%) 
pPDGFRα 13/13 (100%) ND 7/8 (88%) 
RelA 5/6 (83%)§ 2/2§ ND 
RelB 0/6 (0%) ND ND 
cRel 4/5 (80%)║ 0/2 ND 
Beta-catenin 0/8 (0%) ND ND 
*: Results refer to expression in neoplastic cells. 
†: phosphorylated STAT3 stained most MEC04 cells, but only a minority of SNK6 cells. 
‡: performed by flow cytometric immunophenotyping. 
§: cytoplasmic and nuclear staining of neoplastic cells. 
║: cytoplasmic staining of most neoplastic cells. 
ND: not done. 
NE: non evaluable. 
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Table 4. Selection of genes overexpressed in NKTCL tissues compared to PTCL, NOS 
cells with P-value less than 0.005. A complete list of genes is given in the supplementary 
table S2. 
Gene class and specific genes Fold change 
Apoptosis 
BCL2L2 (BCL-W) 1.68 
FASLG (Fas ligand) 5.99 
Cell-to-cell interactions 
ITGAM (Integrin, alpha M) 2.30 
Chemokines 
CCL4 (MIP-1-beta) 4.30 
CCL5 (RANTES) 8.66 
Cytokines & receptors 
IL20 1.15 
IL2RB 2.32 
Growth factors 
TGFB2 1.14 
Cytotoxic molecules 
CTSW (Cathepsin W) 11.31 
GZMA (Granzyme A) 8.03 
GZMB (Granzyme B) 5.39 
GZMH (Granzyme H) 13.66 
PRF1 (Perforin 1) 3.34 
NK cell-associated molecules 
APOBEC3G (Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G) 2.40 
CD244 (NK cell receptor 2B4) 6.75 
KIR2DL3 /// KIR2DS5 10.30 
KIR2DL4 11.77 
KIR2DL5A 7.47 
KIR2DS4 4.94 
KIR3DL1 9.96 
KIR3DL2 14.02 
KIR3DL3 12.51 
KLRC1 /// KLRC2 25.75 
KLRC3 32.96 
KLRC4 /// KLRK1 10.33 
KLRD1 32.45 
NCAM1 (CD56) 10.54 
Immune responses 
IRF6 (Interferon regulatory factor 6) 1.54 
Oncogenes 
MYC 1.18 
RHOC (Ras homolog gene family, member C) 3.22 
Transcription factors 
ATF6 (Activating transcription factor 6) 1.39 
Miscellaneous 
MAPK1 1.46 
PTPN22 (Protein tyrosine phosphatase, non-receptor type 22) 2.47 
YWHAH (Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
eta polypeptide) 1.62 
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Table 5. Copy number alterations identified by aCGH in the NKTCL samples analysed 
in this study. 
 Chromosomes 
Start 
position 
(Mb) 
End 
position 
(Mb) 
No of 
clones 
NKTCL 
tissues and cell 
lines (n=10) 
 NKTCL 
tissues 
(n=8) 
SNK6 SNT8 
G
A
IN
 
1q21-q44 143 245 170 5 3 1 1 
4p16 2 6 5 3 3 0 0 
6p25-p11.1 0 58 93 4 3 1 0 
6q11.1-q14 58 87 26 4 3 1 0 
6q27 167 171 5 3 3 0 0 
7p12-p11.2 53 55 4 5 4 0 1 
7q11.2-q34 62 142 99 5 4 1 0 
7q35-q36 143 156 11 6 5 1 0 
8p23.3 0,13 1,96 5 4 3 1 0 
9q34 134 138 7 4 3 1 0 
10p15 0 4 5 6 6 0 0 
10p15-p14 6 8 6 3 3 0 0 
11p15 0 3 10 4 3 1 0 
16p13.3 1 2 5 4 4 0 0 
17q12 28,81 30,78 12 5 3 1 1 
17q12 29,84 30,30 7 6 4 1 1 
22q11.21 16,15 21,17 6 4 3 0 1 
LO
SS
 
6q16-q25 100 154 75 4 3 1 0 
8p23-p22 4 15 14 3 3 0 0 
11q24-q25 128 133 8 4 3 0 1 
17p13.3 0,34 0,96 6 4 3 1 0 
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Table 6. Selection of pathways differentially expressed in NKTCL tissues compared to 
normal NK cells or PTCL, NOS*. 
Pathway name 
Median P-value 
(compared to 
normal NK cells) 
Median P-value 
(compared to 
PTCL, NOS) 
Apoptosis 
Apoptosis 0.002 < 0.002 
Regulation of BAD phosphorylation 0.109 < 0.018 
PTEN dependent cell cycle arrest and 
apoptosis 0.246 < 0.015 
FAS signalling pathway 0.257 < 0.006 
Cytotoxicity 
Natural killer cell mediated cytotoxicity 0.002 < 0.0001 
Ras-Independent pathway in NK cell-
mediated cytotoxicity 0.325 < 0.0001 
Cell adhesion molecules / extracellular matrix receptor interaction 
Cell communication 0.001 < 0.016 
ECM receptor interaction 0.001 < 0.016 
Focal adhesion 0.001 < 0.023 
Cell adhesion molecules 0.002 < 0.012 
Leukocyte transendothelial migration 0.002 0.371 
Inhibition of matrix metalloproteinases 0.003 0.018 
Integrin signalling pathway 0.003 0.484 
Cell cycle 
Regulation of p27 during phosphorylation < 0.006 0.008 
Cyclin E destruction pathway < 0.041 0.003 
Chemokines / cytokines 
Cytokine cytokine receptor interaction 0.002 < 0.001 
Signal transduction 
JAK-STAT signaling pathway 0.002 0.01 
MAPK signaling pathway 0.002 0.015 
mTOR signaling pathway 0.002 0.06 
NF-κB signaling pathway 0.002 0.06 
TGFβ signaling pathway 0.002 0.019 
VEGF signaling pathway 0.002 0.418 
Notch signaling pathway < 0.005 0.025 
Wnt signaling pathway < 0.005 < 0.013 
AKT signalling pathway 0.14 < 0.001 
*: with a median P-value < 0.02 compared to either normal NK cells or PTCL, NOS.
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FIGURE LEGENDS. 
Figure 1. Validation of gene expression profiling by immunohistochemistry. 
Representative NKTCLs disclosed cytoplasmic staining of neoplastic cells for (A) gzm H, (B) 
EBI3, (C) VEGFA, nuclear localization of (D) pSTAT3, (E) pAKT, cytoplasmic and nuclear 
staining of (F) RelA, and positivity for (G) PDGFRα and (H) pPDGFRα. Images were 
captured with a Zeiss Axioskop2 microscope (Zeiss, Oberkochen, Germany). Photographs 
were taken with a DP70 Olympus camera (Olympus, Tokyo, Japan). Image acquisition was 
performed with Olympus DP Controller 2002, and images were processed with Adobe 
Photoshop v7.0 (Adobe Systems, San Jose, CA). Original magnifications: x400 (A-H). 
Figure 2. Unsupervised clustering of seven NKTCLs, two NKTCL-derived cell lines and 
16 PTCLs, NOS.  Dendrogram of 23 lymphoma tissues and two cell lines based on principal 
component analysis demonstrated two major clusters of NKTCL including tumor-derived cell 
lines and PTCL, NOS, respectively. T1-7: seven NKTCL samples, SNK6, SNT8, C1-16: 16 
PTCL, NOS samples. 
Figure 3. Genomic profiles of NKTCL. Pangenomic view of eight NKTCL tissue samples. 
The horizontal axis represents the genomic order, and the vertical axis represents the number 
of samples with gains or losses. Gains are represented as red bars and losses are represented 
as green bars. 
Figure 4. Quantification of selected genes by qRT-PCR analysis. qRT-PCR analysis for 
(A) MET, (B) TNFRSF21, (C) CCND3, (D) CCL2, and (E) PRDM1, ATG5, AIM1, and 
HACE1 in NKTCL primary tumors and cell lines. The results are expressed as relative fold 
change compared to resting CD3-/CD56+ NK cells sorted from peripheral blood. 
Quantifications were done in duplicate and mean values and standard deviation were 
calculated for each transcript. (A-D) In agreement with the microarray results, mRNA levels 
of MET, CCL2, TNFRSF21 are increased in NKTCL primary tumors compared to normal NK 
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cells whereas CCND3 mRNA is reduced (E) The analysis of four putative tumor suppressors 
in 6q21 region show that the transcripts levels of HACE1, AIM1 and ATG5 are reduced in 
primary tumors and cell lines whereas the mRNA level of PRDM1 is increased in primary 
tumors, due to a wide variation  from case to case (not shown). 
Figure 5. Cellular programs deregulated in NKTCL. Representative molecular pathways 
differentially expressed in NKTCLs by comparison to either normal NK cells (A. JAK-STAT, 
B. angiogenesis, E. apoptosis), normal B cells and ABC-DLBCL (C. NF-κB), normal NK 
cells and normal B cells (D. AKT), or PTCL, NOS (F. cytotoxicity) were illustrated. For each 
line, green corresponds to the minimal intensity value (min), red corresponds to the maximal 
intensity value (max), and black corresponds to (min + max)/2. Several genes related to JAK-
STAT, angiogenesis, and apoptosis-related pathways are overexpressed in NKTCLs 
compared to normal NK cells, and genes related to the cytotoxicity-related pathway are also 
overexpressed in NKTCLs compared to PTCL, NOS. Many genes in the NF-κB and AKT 
signaling pathways are overexpressed in NKTCLs compared to normal B cells, with a 
molecular signature similar to that of ABC-DLBCL in NK-κB pathway. The expression data 
of PDGFRA in NKTCLs, 2 NKTCL-derived cell lines, and normal NK cells is highlighted. 
T1-7: seven NKTCL samples, C1-16: 16 PTCL, NOS samples, AcNK, AcNK02, AcNK08, 
AcNK24: activated NK cells, ReNK, ReNK.: resting NK cells, CB.1-8 and CB.11: nine 
centroblasts samples, CC.1-8 and CC.11: nine centrocytes samples, ABC.2024-2195: 15 
ABC-DLBCL samples. 
Figure 6. Proliferation of NKTCL-derived cell lines in the presence of imatinib mesylate. 
SNK6, MEC04, and U937 cells were incubated for 72 hours in media with or without 
imatinib mesylate at concentrations of 1, 3, and 6 µM. Imatinib induced concentration-
dependent growth inhibition of MEC04 cells. The effect on SNK6 was not significantly 
different from that observed on the myelomonocytic U937 cell line.  The horizontal axis is the 
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concentration of imatinib mesylate. The vertical axis is the percentage of control proliferation. 
Bars indicate the SEM of triplicate experiments. 
Figure 7. Hypothetical representation of signaling pathways involved in NKTCL. The 
interactions of PDGF, AKT, and JAK-STAT signaling pathways may contribute to the 
angiogenesis, immunosuppression, proliferation and survival of NKTCL. 
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